Article
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer.
Medical oncology (Northwood, London, England) - 21 Dec 2019
Westbrook Thomas C, Hagemann Ian S, Ley Jessica, Chen Kevin, Palka Kevin, Liu Jingxia, Chen Ling, Oppelt Peter, Adkins Douglas
Abstract excerpt
We performed a prospective trial to assess the clinical benefit of a tailored gene set built on a next-generation sequencing (NGS) platform in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Archived tumor tissue obtained from patients with recurrent or metastatic HNSCC was analyzed for variants by a tailored Comprehensive Cancer Gene set of 40 genes (CCG-40) performed on a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.